2010
27.07.10
Wragge & Co advises on cross-border life sciences M&A deal
Wragge & Co's Corporate group has advised new client Bioline group on its US $23.3 million (£15.2 million) cross-border acquisition by NASDAQ-listed Meridian Bioscience Inc.
2009
16.11.09
Wragge & Co advises Astex on £300 million drug discovery alliance
Wragge & Co LLP's Life Sciences team has advised long-standing client Astex Therapeutics Limited on a £300 million drug discovery alliance with healthcare giant GlaxoSmithKline (GSK).
24.06.09
Wragge & Co advises Chroma Therapeutics on billion dollar deal double
Wragge & Co LLP's cross-firm life sciences practice has advised biotechnology company Chroma Therapeutics Limited on two simultaneous transactions completed in one day.
17.03.09
Wragge & Co advises Eisai on cross-border €95 million epilepsy deal
Wragge & Co LLP Life Sciences team has advised Eisai Europe Limited on a cross-border €95 million licence and co-promotion agreement with Bial-Portela & CA, S.A for the treatment for epilepsy.
2008
25.11.08
Wragge & Co launches new online dispute resolution tool
Wragge & Co LLP is taking time and initial cost concerns out of instructing lawyers to handle UK disputes with its new online dispute resolution tool - RADAR. RADAR, which stands for Risk: Analyse, Decide and Respond, is fast, free and easy to use.
30.07.08
Wragge & Co advises on cross-border outsourcing deal
Wragge & Co LLP IT team has advised new client Astellas Pharma Europe Ltd. on a pan-European outsourcing agreement.
17.06.08
Wragge & Co Life Sciences team advises Astex on $500 million drug discovery alliance
Wragge & Co LLP Life Sciences team has advised Astex Therapeutics Limited on a landmark $500 million drug discovery alliance with Janssen Pharmaceutica N.V.
28.04.08
Regulatory specialist joins Wragge & Co's Life Sciences team
Wragge & Co LLP has boosted its Life Sciences practice with a new regulatory specialist. Liz Fuller joins as director, life sciences regulatory (US qualified), bringing expertise in pharmaceutical and biotech regulatory affairs.
02.04.08
Wragge & Co's Life Sciences practice grows
Wragge & Co LLP has boosted its Life Sciences practice with the appointment of Dr Luke Kempton as a partner. With significant expertise in life sciences litigation, Luke will be a major force in driving forward the life sciences practice.
26.03.08
Wragge & Co appoints nine new partners
Wragge & Co LLP has appointed nine new partners, investing in key practice areas to deliver continued growth.
2007
20.12.07
Wragge & Co advises Inverness Medical Innovations on UK public takeover
Wragge & Co LLP Corporate Group has advised US client Inverness Medical Innovations, Inc. on its takeover of UK-based BBI Holdings PLC for a total consideration of up to £83 million.18.07.07
Wragge & Co advises AstraZeneca on collaboration with Silence Therapeutics
Wragge & Co LLP Life Sciences Team has advised AstraZeneca on its research and development collaboration with Silence Therapeutics to develop novel respiratory therapeutics.
05.07.07
Wragge & Co completes €41 million cross-border life sciences deal
Wragge & Co LLP's sector-focused Life Sciences Team has completed a €41 million cross-border life sciences deal for Japan's Eisai Co, Ltd.30.03.07
